Navigation Links
Elsevier announces new journal on inflammatory bowel diseases
Date:9/6/2007

Amsterdam, 06 September 2007 Elsevier in partnership with the European Crohns and Colitis Organisation (ECCO) is set to launch the Journal of Crohns and Colitis, a new international journal on inflammatory bowel diseases (IBD). This quarterly journal will be the official journal of the ECCO society and the first print issue will be available in September 2007.

The Journal of Crohn's and Colitis is concerned with the dissemination of knowledge on clinical, basic science and innovative methods related to inflammatory bowel diseases. The journal will publish original articles, review papers, editorials, leading articles, view points, case reports, innovative methods and letters to the editor. Supplemental issues of the journal will be published under a separate title, Journal of Crohn's and Colitis Supplements.

Miquel Gassull, M.D., Ph.D., Hospital Universitari Germans Trias I Pujol in Badalona, Spain and president of ECCO, will serve as the Editor-in-Chief of the new journal. The Editor-in-Chief is joined by a group of prestigious associate editors including Yehuda Chowers, Jean-Frd ric Colombel, Daan Hommes, Jack Satsangi, Stefan Schreiber, Sverine Vermeire and the consensus and guidelines editors Eduard Stange and Simon Travis.

Although it is the official journal of ECCO, the Journal of Crohn?s and Colitis is open to everyone in the world interested and working in the field of inflammatory bowel diseases commented Miquel Gassull. This will become a high quality journal, opening an interactive pathway between clinicians and basic scientists, publishing the best reviews, clinical trials, good observational data, modern epidemiology and relevant breaking news on the diagnosis and therapy of IBD.


'/>"/>

Contact: Koos Admiraal
k.admiraal@elsevier.com
31-204-853-747
Elsevier
Source:Eurekalert

Page: 1

Related medicine news :

1. Partnership Between Diabetes India And Elsevier Announced
2. PM announces a new health care order for India
3. PowderMed Announces Needle-Less Flu Vaccine
4. Ramdoss Announces Introduction of RCH-II
5. Britain Announces Third Transfusion Related Mad Cow Case
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... , ... April 21, 2017 , ... ... it’s been named Agency of Record (AOR) for Theravent, Inc. , the ... snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand distribution ...
(Date:4/21/2017)... ... April 21, 2017 , ... Crossover ... O2X , an active lifestyle company that provides Human Performance Training and ... firefighters, police offers, first responders, military officers and others in service through the ...
(Date:4/21/2017)... , ... April 21, 2017 , ... Alive for ... who wish to overcome their mental health struggles. The Alive team uses advanced ... says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... ... 21, 2017 , ... Northern California Medical Associates ... Symposium on April 1, 2017 in Santa Rosa. This well-attended annual conference plays ... an opportunity to learn about cutting edge treatments, to collaborate, share research and ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... practices, is seeking candidates to serve on its Accreditation and Standards Committees ... “RadSite’s ultimate mission is improving image quality and reducing patient radiation dose,” ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/19/2017)... Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces that it ... 2017 at the Sheraton Hotel in Toronto, Ontario ... the Company is scheduled to present on Tuesday, May 2 at ... Chairman of the Board, Tony Holler will also attend ... For more details ...
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
Breaking Medicine Technology: